ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE
Clinical safety rating
safeAnimal studies have demonstrated safety
Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties; aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis; caffeine is a central nervous system stimulant that antagonizes adenosine receptors.
| Metabolism | Orphenadrine: hepatic N-demethylation and hydroxylation via CYP450 enzymes; Aspirin: hydrolysis to salicylate and conjugation with glycine and glucuronic acid; Caffeine: hepatic metabolism via CYP1A2. |
| Excretion | Orphenadrine: ~60% renal (metabolites, <8% unchanged), ~20% biliary/fecal; Aspirin: ~80-100% renal (salicylates, dose-dependent; alkaline urine increases excretion); Caffeine: ~1-3% renal (unchanged), main metabolites renal. |
| Half-life | Orphenadrine: ~14 hours (range 12-16 h); Aspirin: 2-3 h for low doses, 15-30 h for high/anti-inflammatory doses due to saturable metabolism; Caffeine: 3-6 h in adults, prolonged in liver disease. |
| Protein binding | Orphenadrine: ~30% (albumin); Aspirin: 80-90% (albumin, saturable); Caffeine: 25-36% (albumin). |
| Volume of Distribution | Orphenadrine: ~2.5 L/kg (widespread, CNS penetration); Aspirin: 0.15-0.2 L/kg (low, primarily extracellular); Caffeine: 0.6-0.8 L/kg. |
| Bioavailability | Oral: Orphenadrine ~90%; Aspirin 40-50% (first-pass hydrolysis to salicylate); Caffeine ~100%. |
| Onset of Action | Oral: Orphenadrine 30-60 min; Aspirin 5-30 min (analgesic); Caffeine 15-45 min. |
| Duration of Action | Orphenadrine 4-6 h; Aspirin 3-6 h (analgesic), up to 8 h (anti-inflammatory); Caffeine 3-5 h (stimulant). |
| Molecular Weight | Orphenadrine citrate: 461.5; Aspirin: 180.16; Caffeine: 194.19 |
1-2 tablets (orphenadrine citrate 50 mg, aspirin 770 mg, caffeine 60 mg per tablet) orally every 8-12 hours as needed; maximum 4 tablets per day.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in severe renal impairment (CrCl <30 mL/min). For moderate impairment (CrCl 30-59 mL/min), extend dosing interval to every 12-24 hours. No adjustment for mild impairment (CrCl 60-89 mL/min). |
| Liver impairment | Contraindicated in Child-Pugh class C. For Child-Pugh class B, reduce dose by 50% or extend interval to every 12-24 hours. Use with caution in Child-Pugh class A. |
| Pediatric use | Not recommended for pediatric use due to aspirin's association with Reye's syndrome and lack of safety data for orphenadrine in children. |
| Geriatric use | Use lower end of dosing range (e.g., 1 tablet every 12 hours) due to increased sensitivity to anticholinergic effects and risk of aspirin-induced gastrointestinal bleeding. Avoid use in patients >80 years if possible. |
| 1st trimester | Avoid. Aspirin is associated with increased risk of miscarriage and congenital malformations (e.g., gastroschisis). Caffeine may increase risk of miscarriage. |
| 2nd trimester | Avoid. Aspirin is generally avoided due to risk of premature closure of ductus arteriosus and oligohydramnios; caffeine may affect fetal growth. |
| 3rd trimester | Contraindicated. Aspirin may cause premature closure of ductus arteriosus, oligohydramnios, and bleeding complications in mother and neonate; caffeine may cause neonatal withdrawal. |
Clinical note
Other anticholinergic drugs can have additive effects Can cause drowsiness and dry mouth.
| Placental transfer | All three components cross placenta: orphenadrine (unknown extent), aspirin (significant, metabolized to salicylate), caffeine (freely crosses). |
| Breastfeeding | Use caution. Orphenadrine may reduce milk production; aspirin is excreted in low amounts but risk of Reye's syndrome; caffeine may cause irritability in infant. |
| Lactation Rating | L3 (Moderately Safe) - limited data; potential for adverse effects. |
| Teratogenic Risk | First trimester: Aspirin is associated with increased risk of gastroschisis (ORS 1.5-2.0) and possibly cardiac defects; orphenadrine and caffeine have limited data but caffeine may increase miscarriage risk. Second trimester: Aspirin at high doses may impair fetal renal function; orphenadrine and caffeine effects are not well-studied. Third trimester: Aspirin use after 30 weeks gestation increases risk of premature closure of ductus arteriosus and oligohydramnios; orphenadrine may cause neonatal withdrawal; caffeine may accumulate. |
| Fetal Monitoring | Monitor fetal growth and amniotic fluid volume with serial ultrasound if aspirin used in third trimester. Assess ductus arteriosus patency if near term. Monitor maternal bleeding time and platelet function if high-dose aspirin. Observe neonate for signs of withdrawal (orphenadrine) and caffeine-related irritability. |
| Fertility Effects | Aspirin may interfere with implantation via prostaglandin inhibition; high doses may impair ovulation. Orphenadrine has anticholinergic effects that may reduce cervical mucus quality. Caffeine consumption >300 mg/day may delay time to conception and increase risk of infertility. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Dry mouth |
| Serious Effects |
Hypersensitivity to orphenadrine, aspirin, or caffeinePregnancy (especially third trimester)Breastfeeding (relative contraindication)G6PD deficiencyBleeding disordersPeptic ulcer diseaseSevere hepatic or renal impairmentMyasthenia gravisGlaucomaProstatic hypertrophyTachyarrhythmiasHistory of Reye's syndromeConcomitant use of MAO inhibitors
| Precautions | Avoid in patients with glaucoma, prostatic hypertrophy, or urinary retention due to anticholinergic effects; caution in elderly and those with cardiovascular disease; risk of GI bleeding with aspirin; limit caffeine intake to avoid excessive stimulation. |
| Food/Dietary | Avoid high-tyramine foods (e.g., aged cheeses, cured meats) due to orphenadrine's anticholinergic effects on gut motility. Evening meals high in caffeine may worsen insomnia. Aspirin absorption is delayed by food, but taking with food reduces GI irritation. |
| Clinical Pearls | Orphenadrine citrate has anticholinergic properties; use cautiously in patients with glaucoma, urinary retention, or myasthenia gravis. Aspirin component increases bleeding risk, especially with concurrent anticoagulants. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of salicylism with high doses or hepatic impairment. |
| Patient Advice | Take with food to reduce gastrointestinal upset. · Avoid alcohol while taking this medication. · Do not exceed recommended dosage; may cause dizziness or drowsiness. · Discontinue and seek medical attention if you experience signs of bleeding (e.g., black stools) or allergic reaction. · Inform your doctor if you have a history of stomach ulcers, bleeding disorders, or asthma. |
Loading safety data…